1.
J Pediatric Infect Dis Soc
; 11(7): 337-340, 2022 Jul 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35472147
RESUMO
There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.
